Search results
Results from the WOW.Com Content Network
It affects women twice as frequently as men. Although the inciting event in this process is unknown, clinicopathologic study suggests that compression of the lumen of the nasolacrimal duct is caused by inflammatory infiltrates and edema. This may be the result of an unidentified infection or possibly an autoimmune disease. [citation needed]
Diethylstilbestrol (DES), also known as stilbestrol or stilboestrol, is a nonsteroidal estrogen medication, which is presently rarely used. [5] [6] [7] In the past, it was widely used for a variety of indications, including pregnancy support for those with a history of recurrent miscarriage, hormone therapy for menopausal symptoms and estrogen deficiency, treatment of prostate cancer and ...
Obstruction of the nasolacrimal duct may occur. [4] [5] [6] This leads to the excess overflow of tears called epiphora (chronic low-grade nasolacrimal duct occlusion). [7]A congenital obstruction can cause cystic expansion of the duct and is called a dacryocystocele or Timo cyst.
Brigham and Women’s Hospital. 3. "I predict that in 2025, we will see significant advancements in women's health research. In particular, I hope to see major breakthroughs that improve quality ...
A lack of knowledge about PMDD can make it harder to get a diagnosis or effective treatment. An increasing number of women with PMDD have taken to social media to increase awareness and find ...
Cases of norovirus, a.k.a. the stomach bug, are surging in the U.S. right now. There is no specific medication to treat norovirus. Doctors share tips for feeling better, sooner. The U.S. is seeing ...
The medication was first studied for the treatment of hirsutism in women in 1989. [146] [147] [148] It was the first "pure antiandrogen" to be studied in the treatment of hirsutism. [146] Flutamide was the first NSAA to be introduced, and was followed by nilutamide in 1989 and then bicalutamide in 1995. [149]
A rising number of single women are embarking on parenthood without a partner, figures suggest. Some 6% of in-vitro fertilisation (IVF) cycles in 2022 were for single women, a rise from 2% in 2012 ...